|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mucoepidermoid Carcinoma of the Parotid Gland in Children:A 10-Year Experience显示文摘 | Reza Rahbar J Fredrik Grimmer Sara O Vargas | 2006 | Arch Otolaryngol Head Neck Surg2006，132，： | 1 |
| 2 | Robin sequence: A retrospective review of 115 patients显示文摘 | Adele Karen Evans Reza Rahbar Gary F. Rogers John B. Mulliken Mark S. Volk | 2005 | International Journal of Pediatric Otorhinolaryngology2005，，6： | 1 |
| 3 | Mucoepidermoid Carcinoma of the Parotid Gland in Children:A 1OYear Experience显示文摘 | Reza Rahbar J Fredrik Grimmer Sara O Vargas | 2006 | Arch Otolaryngol Head Neck Surg2006，132，： | 1 |
| 4 | 直肠脱垂修补术应用于男性患者是安全的,但疗效仍不明确显示文摘背景:直肠脱垂在男性中少见,其治疗也鲜有文献报道。本研究旨在评估直肠脱垂修补术应用于男性的手术方式及疗效。方法:本研究为多中心回顾性分析,研究对象为2004-2014年间接受直肠脱垂修补术的连续男性病例。对手术方式及疗效(包括勃起功能和排粪功能)进行评估。结果:58例行直肠脱垂修补术的男性患者纳入研究,手术时平均年龄(52.7624.1)岁。随访时间0.5-117(平均13.2)月。大多数患者进行了内镜评估(78%),仅有少数患者接受了肛门动力学检测(16%)、排粪造影(9%)或直肠超声检查(3%)。10例(17%)患者在修补手术前接受了生物反馈/盆底生理治疗。19例(33%)患者行经会阴修补术(多为经会阴直肠乙状结肠切除术);39例(67%)行经腹修补术(均为缝扎固定术),其中77%采用微创技术完成。总并发症发生率为26%,其中尿潴留发生率为16%[经会阴手术较经腹手术更为常见(32%vs 8%,P=0.028)],尿路感染发生率7%,切口感染发生率3%。术后总体复发率为9%,但经腹与经会阴手术复发率的差异无统计学意义。大多数患者性功能方面的信息缺失,无论是手术前(76%)还是手术后(78%)。结论:直肠脱垂修补术应用于男性患者是安全的,且术后复发率低。但各个中心都没有能做好性功能方面的信息采集。进一步研究需要评估男性直肠脱垂的最佳修补术式以及功能学结果。 | Vitaliy Y.Poylin Jennifer L.Irani Reza Rahbar Muneera R.Kapadia | 2019 | Gastroenterology Report2019，7，4： | 0 |
| 5 | A Review of the Role of ERp57 in Cancerous and Non-Cancerous Cell Physiology and its Potential as a Therapeutic Target显示文摘The protein ERp57 is a stress-responsive protein,mainly exists in the endoplasmic reticulum(ER),and a small amount in the cell membrane,cytoplasm,nucleus and mitochondria,which is involved in the signal transduction from the cell surface,the regulation process that occurs in the nucleus,and the formation of polymer protein complexes involved in DNA repair.Various degrees of ERp57 dysregulation has been observed in many types of non-communicable diseases especially in cancers.Previous studies showed that the expression of ERp57 could play a key role in occurrence and development of cancers such as breast cancer,gastric cancer,ovarian cancer,etc.;in addition,it has been suggested to play a pivotal role in disease progression of non-cancerous diseases such as neurodegeneration,liver disease,kidney disease,intestinal irritability syndrome and airway hypersensitivity.Thus,abnormal expression of ERp57 could be used as promising biomarker for cancer diagnosis and prognosis based on the previous studies.In this regard,current study was aimed to review the literature,which have been elucidate the role of ERp57 protein expression in both non-cancer and cancer disease.Overall,most studies have shown that inhibiting/knocking out of ERp57 could inhibit the cell proliferation and also induce apoptosis in both human cancerous and non-cancerous cells.Also,it has been suggested that the overexpression of ERp57 could intensify the cancer development.Therefore,it could be hypothesized that targeting of ERp57 might be a potential treatment in cancerous and non-cancerous diseases. | Fatemeh Rahbar Avid Farhang Fagheh Ayda Khosravi Siavash Shariatzadeh Reza Akhavan-Sigari | 2021 | Molecular & Cellular Biomechanics2021，18，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员